Clinical Trial Update: Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of umbralisib in non-follicular indolent non-Hodgkin lymphoma has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma
• Non Follicular Indolent Non-hodgkin Lymphoma
• Waldenstrom Macroglobulinemia

Drugs mentioned

• umbralisib

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2023-06-23